Melanoma

A multipeptide vaccine combination approach may extend survival in stage IIB to IV melanoma.

A biologics license application has been accepted by the FDA for subcutaneous nivolumab to treat adult patients eligible for approved solid tumor nivolumab indications

Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased immune-related adverse effects.

Patients with unresectable or metastatic melanoma treated with the universal cancer vaccine UV1 plus nivolumab and ipilimumab did not experience an improvement in progression-free survival vs nivolumab plus ipilimumab alone.

Two experts commented on ways oncology nurses can learn more about administering TIL therapy and how they can play a supportive role for patients receiving the treatment.

The rate of initiating immunotherapy towards the end of life in patients with advanced cancers, including renal cell carcinoma, melanoma, and non-small cell lung cancer, is increasing over time.

Jeanelle S. King, PA-C, provides an in-depth look at nivolumab-relatlimab in a downloadable reference sheet.

Screening for financial toxicity should be routine in cancer care, according to investigators.

The FDA has approved adjuvant nivolumab to treat completely resected stage IIB/C melanoma.

At 85.3 months follow-up, the median overall survival with pembrolizumab was 32.7 months vs 15.9 months with ipilimumab.

ASCO has updated its recommendations for systemic therapies in melanoma.

APRNs developed a discharge program which reduced readmission rates for patients receiving immunotherapy for advanced melanoma.

The FDA approved pembrolizumab (Keytruda) for the adjuvant treatment of patients with resected, high-risk stage III melanoma.